Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul 5;17(1):120-126.
doi: 10.5114/aoms.2018.76953. eCollection 2021.

Serum interleukin-23 protects, whereas methotrexate treatment stimulates selected components of the metabolic syndrome in patients with SAPHO syndrome

Hanna Przepiera-Będzak  1 , Katarzyna Fischer  2 , Marek Brzosko  1
Affiliations

Serum interleukin-23 protects, whereas methotrexate treatment stimulates selected components of the metabolic syndrome in patients with SAPHO syndrome

Hanna Przepiera-Będzak et al. Arch Med Sci. .

Abstract

Introduction: The aim of the study was to evaluate the impact of disease activity, selected serum cytokines, and therapy on metabolic syndrome (MetS) components in patients with synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome.

Material and methods: We studied 46 SAPHO patients (40 women, 6 men). We recorded age, sex, disease duration, arthritis localization, type of skin changes, bone scintigraphy results, comorbidities, BASDAI, VAS, and treatment. We measured erythrocyte sedimentation rate, C-reactive protein, lipid profile, serum IL-6, IL-18, IL-23, endothelin-1, vascular endothelial growth factor, and epidermal growth factor (EGF).

Results: 97.8% of patients had sternoclavicular joint arthritis, 91.3% of patients palmoplantar pustulosis. In 65.2% of SAPHO patients skin changes and arthritis started simultaneously. Apart from non-steroidal anti-inflammatory drugs, patients were treated with methotrexate (41.3%), sulfasalazine (41.3%), and antibiotics (39.1%). 19.5% of patients met MetS criteria. Serum IL-23 correlated positively with total cholesterol (TC; p = 0.02) and high-density lipoprotein cholesterol (HDL-C) (p = 0.01) in the SAPHO group. There was a negative correlation between HDL-C and BASDAI (p = 0.02). Patients treated with methotrexate had higher triglyceride (p = 0.01) and low-density lipoprotein cholesterol (LDL-C) (p = 0.01) levels. There was a negative correlation between TC and EGF (p = 0.03). Increased prevalence of autoimmune diseases and depression was observed in SAPHO patients.

Conclusions: Serum IL-23 protects, whereas methotrexate treatment stimulates selected components of the MetS in patients with SAPHO syndrome.

Keywords: SAPHO; interleukin-23; lipid profile; metabolic syndrome; methotrexate.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Chamot AM, Benhamou CL, Kahn MF, Beraneck L, Kaplan G, Prost A. Le syndrome acné pustulose hyperostose ostéite (SAPHO). Résultats d’une enquête nationale. 85 observations. Rev Rhum Mal Osteoartic. 1987;54:187–96. - PubMed
    1. Kahn MF, Kahn MA. The SAPHO syndrome. Bailliere Clin Rheumatol. 1994;8:333–62. - PubMed
    1. Schilling F, Kessler St. Das SAPHO syndrome: klinisch-rheumatologische und radiologische differenzierung und klassifizierung eines krankengutes von 86 fällen. Z Rheumatol. 2000;59:1–28. - PubMed
    1. Colina M, Govoni M, Orzincolo C, Trotta F. Clinical and radiological evolution of synovitis, acne, pulstulosis, hyperostosis and osteitis syndrome: a single center study of a cohort of 71 subjects. Arthritis Rheum. 2009;61:813–21. - PubMed
    1. Hayem G, Bouchaud-Chabot A, Benali K, et al. SAPHO syndrome: a long-term follow-up study of 120 cases. Semin Arthritis Rheum. 1999;29:159–71. - PubMed